EN · OpenOnco · DIS-ENDOMETRIAL — Auto-stub (88% наповненість)
← Back to galleryFeedback on this caseUA
OpenOnco · Treatment Plan
Treatment plan — DIS-ENDOMETRIAL
PLAN-AUTO-ENDOMETRIAL-001-V1 · v1 · 2026-04-27
Patient
AUTO-ENDOMETRIAL-001 · Algorithm: ALGO-ENDOMETRIAL-ADVANCED-1L

Clinical significance of mutations (ESCAT / OncoKB)

Tumor-board context — the engine does not use these tiers to rank tracks
BiomarkerVariantESCATOncoKBClinical significanceDrugsSources
No clinically actionable variants matched in this profile.

Treatment options (2 tracks)

Standard plan
★ DEFAULT
Indication
IND-ENDOMETRIAL-ADVANCED-1L-PEMBRO-CHEMO
Regimen
Pembrolizumab + carbo + paclitaxel (endometrial advanced 1L)
Drugs + NSZU
  • Pembrolizumab (DRUG-PEMBROLIZUMAB) 200 mg IV q3w · Continuous up to 2 years · IV ⚠ NSZU — not for this indication
  • Carboplatin (DRUG-CARBOPLATIN) AUC 5 IV · Day 1 x 6 cycles · IV ⚠ NSZU — not for this indication
  • Paclitaxel (DRUG-PACLITAXEL) 175 mg/m² IV · Day 1 x 6 cycles · IV ⚠ NSZU — not for this indication
Reason
Engine default per algorithm ALGO-ENDOMETRIAL-ADVANCED-1L: {'step': 1, 'outcome': False, 'branch': {'result': 'IND-ENDOMETRIAL-ADVANCED-1L-PEMBRO-CHEMO'}, 'fired_red_flags': [], 'winner_red_flag': None}
Aggressive plan
Indication
IND-ENDOMETRIAL-ADVANCED-1L-DOSTARLIMAB-CHEMO
Regimen
Dostarlimab + carbo + paclitaxel (endometrial advanced 1L dMMR)
Drugs + NSZU
  • Dostarlimab (DRUG-DOSTARLIMAB) 500 mg IV q3w → 1000 mg q6w maintenance · With chemo cycles 1-6 + maintenance up to 3 years · IV ✗ Not registered in UA
  • Carboplatin (DRUG-CARBOPLATIN) AUC 5 IV · Day 1 x 6 cycles · IV ⚠ NSZU — not for this indication
  • Paclitaxel (DRUG-PACLITAXEL) 175 mg/m² IV · Day 1 x 6 cycles · IV ⚠ NSZU — not for this indication
Reason
Alternative track presented for HCP consideration

Pre-treatment investigations

Investigations before treatment start · critical / standard / desired · merged across tracks
IDNamePriorityCategoryNeeded for
TEST-CECT-CAPКТ органів грудної клітки/черевної порожнини/таза з внутрішньовенним контрастуваннямCriticalimagingall tracks
TEST-ER-PR-IHCІГХ ЕР + ПР на пухлиніCritical—all tracks

Timeline

Treatment timeline — derived from regimen + monitoring schedule

Standard plan

Induction · Pembrolizumab + carbo + paclit
21-day cycles × Chemo x 6; pembro maintenance up to 2 years

Aggressive plan

Induction · Dostarlimab + carbo + paclitax
21-day cycles × Chemo x 6; dostarlimab maintenance up to 3 years

MDT brief

Skills (recommended) — for consideration (1)

  • Клінічний фармацевт recommended
    Хіміоімунотерапевтичний схема — drug-drug interactions, dose adjustments, premedication.
    skill: clinical_pharmacistv0.1.0reviewed 2026-04-25STUBsign-offs: 0lead: TBD

Open questions (1, 0 blocking)

  • OQ-LDH-CURRENT
    Який актуальний LDH? Маркер пухлинного навантаження і трансформації.
    LDH входить у прогностичні індекси індолентних лімфом.
    → hematologist

Data quality

  • Unevaluated RedFlags: RF-ENDOMETRIAL-FRAILTY-AGE, RF-ENDOMETRIAL-HIGH-RISK-BIOLOGY, RF-ENDOMETRIAL-INFECTION-SCREENING, RF-ENDOMETRIAL-ORGAN-DYSFUNCTION, RF-ENDOMETRIAL-TRANSFORMATION-PROGRESSION

Skill catalog (1/16 activated in this plan)

All registered virtual specialists. ✓ — activated for this case; ○ — not activated (available for other clinical scenarios).
Specialistskill_idVersionLast reviewedSign-offsDomain
Specialist з клітинної терапії (CAR-T)cellular_therapy_specialistv0.1.02026-04-250cellular_therapy
Клінічний фармацевтclinical_pharmacistv0.1.02026-04-250clinical_pharmacy
Гематолог / онкогематологhematologistv0.1.02026-04-250hematology_oncology
Гематопатолог (специфічно для лімфом / лейкозів / мієломи)hematopathologistv0.1.02026-04-250hematopathology
Інфекціоніст / гепатологinfectious_disease_hepatologyv0.1.02026-04-250infectious_diseases
Медичний онколог (хіміотерапевт солідних пухлин)medical_oncologistv0.1.02026-04-250solid_oncology
Молекулярний генетик / молекулярний онкологmolecular_geneticistv0.1.02026-04-250molecular_oncology
Паліативна допомогаpalliative_carev0.1.02026-04-250palliative_care
Патолог (загальний)pathologistv0.1.02026-04-250pathology
Сімейний лікар / терапевтprimary_carev0.1.02026-04-250primary_care
Психолог / онкопсихологpsychologistv0.1.02026-04-250psychosocial
Радіотерапевт (променева терапія)radiation_oncologistv0.1.02026-04-250radiation_oncology
Лікар-радіологradiologistv0.1.02026-04-250diagnostic_imaging
Соціальний працівник / кейс-менеджерsocial_worker_case_managerv0.1.02026-04-250psychosocial
Хірург-онкологsurgical_oncologistv0.1.02026-04-250surgical_oncology
Specialist з трансплантації (BMT)transplant_specialistv0.1.02026-04-250cellular_therapy

Sources cited

Експериментальні опції (клінічні дослідження)

Третій трек плану — open-enrollment trials з ClinicalTrials.gov. Останнє оновлення: 2026-04-27. Render-time metadata; engine selection не змінюється цим блоком (CHARTER §8.3).
NCTNamePhaseСтатусСпонсорUAВключення (фрагмент)
NCT06333314Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIPHASE2RECRUITINGUNICANCER—
NCT06533332A Phase 1 Trial of ERX-315 in Participants With Advanced Solid TumorsPHASE1RECRUITINGEtiraRx Australia Pty Ltd—
NCT04585750The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)PHASE1 / PHASE2RECRUITINGPMV Pharmaceuticals, Inc—
NCT06028724A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)N/ARECRUITINGCentro di Riferimento Oncologico - Aviano—
NCT04486352A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerPHASE1 / PHASE2RECRUITINGAlliance Foundation Trials, LLC.—
NCT06656949Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium CancerNARECRUITINGQilu Hospital of Shandong University—
NCT06270706A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPHASE1RECRUITINGPliant Therapeutics, Inc.—
NCT03621904PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial CancerN/ARECRUITINGRadboud University Medical Center—
NCT05520099Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic PlatformN/ARECRUITINGElephas—
NCT02012699Integrated Cancer Repository for Cancer ResearchN/ARECRUITINGUniversity of Nebraska—

Перевіряти статус набору безпосередньо у дослідницькому центрі. Дані ctgov можуть відставати від поточного статусу UA-сайтів.

Доступність опцій в Україні

Per-track UA registration · НСЗУ · cost · access pathway. Render-time metadata; engine selection не залежить від цих полів (CHARTER §8.3).
ОпціяРеєстрація UAНСЗУCost orientationAccess pathway
Standard plan
Pembrolizumab + carbo + paclitaxel (endometrial advanced 1L) (REG-PEMBRO-CARBO-PACLI-ENDOM)
✓ зареєстровано✓ покривається₴-? — verify pathwayНСЗУ formulary
Aggressive plan
Dostarlimab + carbo + paclitaxel (endometrial advanced 1L dMMR) (REG-DOSTARLIMAB-CARBO-PACLI-ENDOM)
1/3 component drug(s) not registered in Ukraine +1
✗ не зареєстровано✗ out-of-pocket₴-? — verify pathwaynot recorded
Trial · NCT06333314
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06533332
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04585750
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06028724
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT04486352
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06656949
Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT06270706
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT03621904
PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT05520099
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor
Trial · NCT02012699
Integrated Cancer Repository for Cancer Research
No UA site listed — international referral required
— невідомо— невідомо
self-pay: ₴0/course
Trial sponsor

Інформація про ціни — orientation. Перевіряти у конкретній аптеці / foundation / трайл-сайті. Status updated: 2026-04-27.

plan_id: PLAN-AUTO-ENDOMETRIAL-001-V1 | version: 1 | generated: 2026-04-27T10:14:01.593853+00:00
Per FDA non-device CDS positioning (CHARTER §15): Outpatient oncology treatment planning to support tumor-board discussion. Not a medical device; not for autonomous clinical decision-making.
Per FDA non-device CDS positioning (CHARTER §15): Both treatment options below are presented for review. The engine's selection of a 'recommended' default does not constitute a clinical decision. Final treatment selection requires HCP judgment incorporating information not available to the system.
This document is an informational resource supporting tumor-board discussion (per CHARTER §11). It is not a system that makes clinical decisions. Every recommendation must be verified by the treating physician.